Evidence map›Paper›PMID 30642838›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019

Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk.

Christine M Lusk, Angela S Wenzlaff, Donovan Watza, Jessica C Sieren, Natasha Robinette, Garrett Walworth, Michael Petrich, Christine Neslund-Dudas, Michael J Flynn, Thomas Song and 5 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Christine M LuskKarmanos Cancer Institute, Detroit, Michigan.
Angela S WenzlaffKarmanos Cancer Institute, Detroit, Michigan.ORCID 0000-0001-8669-8240
Donovan WatzaKarmanos Cancer Institute, Detroit, Michigan.
Jessica C SierenDepartment of Radiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa.ORCID 0000-0002-1109-7886
Natasha RobinetteDepartment of Radiology, Karmanos Cancer Institute, Detroit, Michigan.
Garrett WalworthDepartment of Radiology, Karmanos Cancer Institute, Detroit, Michigan.
Michael PetrichDepartment of Radiology, Karmanos Cancer Institute, Detroit, Michigan.
Christine Neslund-DudasDepartment of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Michael J FlynnDepartment of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Thomas SongDepartment of Radiology, Henry Ford Health System, Detroit, Michigan.
David SpizarnyDepartment of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Michael J SimoffJosephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
Ayman O SoubaniKarmanos Cancer Institute, Detroit, Michigan.
Shirish GadgeelComprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
Ann G SchwartzKarmanos Cancer Institute, Detroit, Michigan. schwarta@karmanos.org.
Henry Ford Health System · USWayne State University · USThe Barbara Ann Karmanos Cancer Institute · USMichigan Center for Translational Pathology · USUniversity of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Inflammation Pathways and COPD in the Development of Lung CancerR01CA141769 · NCI · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G. · 2011 to 2016
$8.7M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
Multi-center Structural & Functional Quantitative CT Pulmonary PhenotypingR01HL112986 · NHLBI · UNIVERSITY OF IOWA · PI HOFFMAN, ERIC ALFRED · 2012 to 2016
$4.6M
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS--SEERN01PC065064 · PC · WAYNE STATE UNIVERSITY · PI WEISS, LINDA K · 1996 to 2000
$4.5M
CCR NIH HHS HHSN261201300011CNCI NIH HHS HHSN261201300011INCI NIH HHS N01 PC065064NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA141769NHLBI NIH HHS R01 HL112986NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is a heterogeneous condition with respect to onset, progression, and response to therapy. Incorporating clinical- and imaging-based features to refine COPD phenotypes provides valuable information beyond that obtained from traditional clinical evaluations. We characterized the spectrum of COPD-related phenotypes in a sample of former and current smokers and evaluated how these subgroups differ with respect to sociodemographic characteristics, COPD-related comorbidities, and subsequent risk of lung cancer.

methodsWhite (

resultsFive clusters were identified that differed significantly with respect to sociodemographic (e.g., race, age) and clinical (e.g., BMI, limitations due to breathing difficulties) characteristics. Increased risk of lung cancer was associated with increasingly detrimental lung function clusters (when ordered from most detrimental to least detrimental).

conclusionsMeasures of lung function vary considerably among smokers and are not fully explained by smoking intensity. IMPACT: Combining clinical (spirometry) and radiologic (qCT) measures of COPD defines a spectrum of lung disease that predicts lung cancer risk differentially among patient clusters.

Indexed as

Diagnostic ImagingFemaleHumansLung NeoplasmsMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRisk FactorsSmoking

Identifiers

PMID30642838
PMCPMC6449213
OpenAlexW2909460670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.